Tyra Biosciences, Inc.

NasdaqGS TYRA

Tyra Biosciences, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -19,938.65%

Tyra Biosciences, Inc. Operating Income Margin is -19,938.65% for the Trailing 12 Months (TTM) ending September 30, 2024. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

NasdaqGS: TYRA

Tyra Biosciences, Inc.

CEO	Dr. Todd Harris Ph.D.
IPO Date	Sept. 15, 2021
Location	United States
Headquarters	2656 State Street
Employees	49
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Pharmaceuticals Plastics Robotics

Description

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

Key trends

Past 5 years